This trial is active, not recruiting.

Condition preterm delivery
Sponsor Esoterix Genetic Laboratories, LLC
Start date March 2010
End date July 2012
Trial size 2000 participants
Trial identifier NCT01009723, GGPS0001


This protocol seeks to longitudinally collect blood samples from a cohort of pregnant women. The biological specimens will be used to determine the predictive power of biochemical markers routinely used in Down syndrome screening in the assessment of patient's risk of preterm delivery.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - The participant understands the nature of the study and its requirements. To this end, we will require that the participants have command of the English language. - The participant consents to and signs the approved consent form. - The participant is 18 years of age or older. - The participant has a singleton pregnancy. - The participant is planning on continuing the pregnancy. - The participant has intent to clinically test for Down syndrome risk. - The participant consents to the study at the first trimester of her pregnancy. - The participant understands the nature of the study and its requirements. To this end, we will require that the participants have command of either the English or Spanish language. Exclusion Criteria: - N/A

Additional Information

Official title Early Prediction Of Preterm Delivery By Measurement Of Maternal Serum Markers
Description The study will investigate whether the levels of individual maternal serum screening biomarkers, their combinations or temporal changes in the level can be associated with an increased risk of preterm delivery. Blood samples at three time points in pregnancy will be collected from the study participants. The first two blood draws will be timed to coincide with the first and second trimester maternal serum testing. The third blood draw will coincide with the screening for gestational diabetes. Pregnancy outcome information will be collected from the physicians and linked to the subject samples. Subject samples from a case-control patient group will be analyzed by the serum screening biochemical assay. Statistical analyses will be performed to achieve the study objectives. NOTE: This study is recruiting in Florida, USA. The laboratory data coordination is being performed in Massachusetts, USA and New Mexico, USA. New study locations will be identified on an ongoing basis.
Trial information was received from ClinicalTrials.gov and was last updated in June 2012.
Information provided to ClinicalTrials.gov by Esoterix Genetic Laboratories, LLC.